In 2024, R&D must still be capitalized and amortized (5-year domestic, 15-year foreign) while bonus depreciation has dropped to 60%, which is pushing up cash taxes for many mid-market businesses. How are you adjusting forecasts and planning around this alongside potential exposure to the IRA’s 15% corporate AMT and uneven state conformity? General information only — please consult a qualified attorney for specific situations.